medigraphic.com
Academia Mexicana de Neurología, A.C.

2009, Number 1

<< Back Next >>

Rev Mex Neuroci 2009; 10 (1)

Treatment of neuromuscular disorders with immunoglobulin and plasmapheresis

Porras-Betancourt M

Language: Spanish
References: 86
Page: 18-29
PDF size: 90.26 Kb.


ABSTRACT

There are several immunomediated diseases of the peripheral nervous system, such as muscular, nervous and neuromuscular junction abnormalities. Thinking about de immunological basis of those illnesses, the treatment is immunomodulated and immunoregulated-based. Both intravenous immunoglobulin and plasma exchange are considerate as immunomodulatory therapies which delay the progression and improve the patients’ quality of life. This review focuses in the indications of these treatments en peripheral nervous system diseases.


REFERENCES

  1. Chitnis T, Khoury SJ. Immunologic neuromuscular disorders. J Allergy Clin Immunol 2003; 111: S659-68.

  2. Kokontis L, Gutmann L. Current treatment of neuromuscular diseases. Arch Neurol 2000; 57: 939-43.

  3. Lehmann HC, Hartung HP, Gerd RH, Stuve O, Kieseier BC. Plasma exchange in neuroimmunological disorders. Part 1: rationale and treatment of inflammatory central nervous system disorders. Arch Neurol 2006; 63: 930-5.

  4. Korach JM, Berger P, Giraud C, Le Perff-Desman C, Chillet P. French Registry Cooperative Group. Role of replacement fluids in the immediate complications of plasma exchange. Intensive Care Med 1998; 24: 452-8.

  5. Szczepiorkowski ZM, Bandarenko N, Kim HC, Linenberger ML, et al. Guidelines on the Use of Therapeutic apheresis in clinical practice-Evidence- Based Approach from the Apheresis Applications Committee of the American Society for Apheresis. J Clinic Apheresis 2007; 22: 106-75.

  6. Assessment of plasmapheresis. Report of the therapeutics and technology assessment subcommittee of the American academy of neurology. Neurology 1996; 47: 840-3.

  7. Weinstein R. Therapeutic apheresis in neurological disorders. J Clin Apheresis 2000; 15: 74-128.

  8. Guillain-Barré Syndrome Study Group. Plasmapheresis and acute Guillain-Barré syndrome. Neurology 1985; 35: 1096-104.

  9. French Cooperative Group on Plasma Exchange in Guillain-Barré Syndrome. Efficiency of plasma exchange in Guillain-Barré syndrome. Ann Neurol 1987; 22: 753-61.

  10. French Cooperative Group on Plasma Exchange in Guillain-Barré Syndrome. Plasma exchange in Guillain-Barré syndrome. Ann Neurol 1992; 32: 94-7.

  11. Randomised trial of plasma exchange, intravenous immunoglobulin, and combined treatments in Guillain-Barré syndrome. Plasma Exchange/Sandoglobulin Guillain-Barré Syndrome Trial Group. Lancet 1997; 349: 225-30.

  12. Dada MA, Kaplan AA. Plasmapheresis treatment in Guillain-Barré syndrome: potential benefit over IVIg in patients with axonal involvement. Ther Apher Dial 2004; 8: 409-12.

  13. Raphael JC, Chevret S, Hughes RA, Annane D. Plasma exchange for Guillain-Barre syndrome. Cochrane Database Syst Rev 2001: CD001798.

  14. French Cooperative Group on Plasma Exchange in Guillain-Barré Syndrome. Appropriate number of plasma exchanges in Guillain- Barré syndrome. Ann Neurol 1997; 41: 298-306.

  15. Haupt WF. Recent advances of therapeutic apheresis in Guillain- Barre syndrome. Ther Apher. 2000; 4: 271-4.

  16. Khalili-Shirazi A, Atkinson P, Gregson N, Hughes RA. Antibody responses to P0 and P2 myelin proteins in Guillain-Barré syndrome and chronic idiopathic demyelinating polyradiculoneuropathy. J Neuroimmunol 1993; 46: 245-51.

  17. Kieseier BC, Dalakas MC, Hartung HP. Immune mechanisms in chronic inflammatory demyelinating neuropathy. Neurology 2002; 59: S7- S17.

  18. Toyka KV, Gold R. The pathogenesis of CIDP: rationale for treatment with immunomodulatory agents. Neurology 2003; 60:S2-S7.

  19. Sutton IJ, Winer JB. Immunosuppression in peripheral neuropathy: rationale and reality. Curr Opin Pharmacol 2002; 2: 291-5.

  20. Mehndiratta MM, Hughes RA, Agarwal P. Plasma exchange for chronic inflammatory demyelinating polyradiculoneuropathy. Cochrane Database Syst Rev 2004(3): CD003906.

  21. Dyck PJ, Daube J, O’Brien P, et al. Plasma exchange in chronic inflammatory demyelinating polyradiculoneuropathy. N Engl J Med 1986; 314: 461-5.

  22. Hahn AF, Bolton CF, Pillay N, et al. Plasma-exchange therapy in chronic inflammatory demyelinating polyneuropathy. Brain 1996; 119: 1055-66.

  23. Dyck PJ, Litchy WJ, Kratz KM, et al. A plasma exchange versus immune globulin infusion trial in chronic inflammatory demyelinating polyradiculoneuropathy. Ann Neurol 1994; 36: 838-45.

  24. Ropper AH, Gorson KC. Neuropathies associated with paraproteinemia. N Engl J Med 1998; 338: 1601-7.

  25. Dyck PJ, Low PA, Windebank AJ, et al. Plasma exchange in polyneuropathy associated with monoclonal gammopathy of undetermined significance. N Engl J Med 1991; 325: 1482-6.

  26. Simovic D, Gorson KC, Ropper AH. Comparison of IgM MGUS and IgG-MGUS polyneuropathy. Acta Neurol Scand1998; 97: 194-200.

  27. Vincent A, Drachman DB. Myasthenia gravis. Adv Neurol 2002; 88: 159-88.

  28. De Baets M, Stassen MH. The role of antibodies in myasthenia gravis. J Neurol Sci 2002; 202: 5-11.

  29. Hoch W, McConville J, Helms S, Newsom-Davis J, Melms A, Vincent A. Autoantibodies to the receptor tyrosine kinase MuSK in patients with myasthenia gravis without acetylcholine receptor antibodies. Nat Med 2001; 7: 365-8.

  30. National Institutes of Health Consensus Development Conference. The use of therapeutic plasmapheresis for neurological disorders. Transfus Med Rev 1988; 2: 48-53.

  31. Assessment of plasmapheresis: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology 1996; 47: 840-3.

  32. Gajdos P, Chevret S, Clair B, Tranchant C, Chastang C. Myasthenia Gravis Clinical Study Group. Clinical trial of plasma exchange and high-dose intravenous immunoglobulin in myasthenia gravis. Ann Neurol 1997; 41: 789-96.

  33. Gajdos P, Chevret S, Toyka K. Intravenous immunoglobulin for myasthenia gravis. Cochrane Database Syst Rev 2003(2): CD002277.

  34. SandersDB.Lambert-Eatonmyasthenicsyndrome: clinicaldiagnosis, immune-mediated mechanisms, and update on therapies. Ann Neurol 1995; 37(Suppl. 1): S63-S73.

  35. Lang B, Waterman S, Pinto A, et al. The role of autoantibodies in Lambert-Eaton myasthenic syndrome. Ann N Y Acad Sci 1998; 841: 596-605.

  36. Newsom-Davis J, Murray NM. Plasma exchange and immunosuppressive drug treatment in the Lambert-Eaton myasthenic syndrome. Neurology 1984; 34: 480-5.

  37. Lemm G. Composition and properties of IVIg preparations that affect tolerability and therapeutic efficacy. Neurology 2002; 59(Suppl. 6): S28-S32.

  38. Kazatchkine MD, Kaveri SV. Advances in immunology: immunomodulation of autoimmune and inflammatory diseases with intravenous immune globulin. N Engl J Med 2001; 345: 747-55.

  39. Dalakas MC. Mechanisms of action of IVIg and therapeutic considerations in the treatment of acute and chronic demyelinating neuropathies. Neurology 2002; 59(Suppl. 6): S13-S21.

  40. Dalakas MC. Intravenous immunoglobulin therapy for neurological diseases. Ann Intern Med 1997; 126: 721-30.

  41. Diegel M, Rankin B, Bolen J, Dubois P, Kiener P. Cross linking of Fc receptor to surface immunoglobulin on B cells provides an inhibitory signal that closes the plasma membrane calcium channel. J Biol Chem 1994; 269: 11409-16.

  42. Yu Z, Lennon VA. Mechanism of intravenous immune globulin therapy in antibody-mediated autoimmune diseases. N Engl J Med 1999; 340: 227–228.

  43. Ankrust P, Muller F, Svenson M, Nordoy I, Bendtzen K, Froland SS. Administration of intravenous immunoglobulin (IVIg) in vivo down-regulatory effects on the IL-1 system. Clin Exp Immunol 1999; 115: 136-43.

  44. Kieseier BC, Kiefer R, Clements JM, et al. Matrix metalloproteinase-9 and -7 are regulated in experimental autoimmune encephalomyelitis. Brain 1998; 121: 159-66.

  45. Damĺs JK, Gullestad L, Aass H, et al. Enhanced gene expression of chemokines and their corresponding receptors in mononuclear blood cells in chronic heart failure-modulatory effect of intravenous immunoglobulin. J Am Coll Cardiol 2001; 38: 187-93.

  46. Basta M, Dalakas MC. High-dose intravenous immunoglobulin exerts its beneficial effect in patients with dermatomyositis by blocking endomysial deposition of activated complement fragments. J Clin Invest 1994; 94: 1729-35.

  47. Leung DY, Burns JC, Newburger JW, Geha RS. Reversal of lymphocyte activation in vivo in the Kawasaki syndrome by intravenous gammaglobulin. J Clin Invest 1987; 79: 468-72.

  48. Rigal D, Vermot-Desroches C, Heitz S, Bernaud J, Alfonsi F, Monier JC. Effect of IVIg in peripheral blood B, NK, and T cell subpopulations in women with recurrent spontaneous abortions: specific effect on LFA-1 and CD56 molecules. Clin Immunol Immunopathol 1994; 71: 309-14.

  49. Blasczyk R, Westhoff V, Grosse-Wilde H. Soluble CD4, CD8 and HLA molecules in commercial immunoglobulin preparations. Lancet 1993; 341: 789-90.

  50. Darabi K, Abdel-Wahab O, Dzik WH. Current usage of intravenous immune globulin and the rationale behind it: the Massachusetts General Hospital data and a review of the literature. Transfusion 2006; 46: 741-53.

  51. Dalakas MC. Intravenous Immunoglobulin in the treatment of autoimmune neuromuscular diseases: present status and practical therapeutic guidelines Muscle Nerve 1999; 22: 1479-97.

  52. Misra N, Bayry J, Ephrem A, Dasgupta S, et al. Intravenous immunoglobulin in neurological disorders: a mechanistic perspective. J Neurol 2005; 252[Suppl. 1]: 1-6.

  53. Hartung HP, Pollard JD, Harvey GK, Toyka KV. Immunopathogenesis and treatment of the Guillain-Barre’ syndrome-part II. Muscle Nerve 1995; 18: 154-64.

  54. van der Meche FGA, Schmitz PIM, and the Dutch Guillain-Barré Study Group. A randomized trial comparing intravenous immune globulin and plasma exchange in Guillain-Barré syndrome. N Engl J Med 1992; 326: 1123-9.

  55. Raphael JC, Chevret S, Harboun M, Jars-Guincestre MC. Intravenous immune globulins in patients with Guillain-Barre syndrome and contraindications to plasma exchange: 3 days versus 6 days. J Neurol Neurosurg Psychiatry 2001; 71: 235-8.

  56. Ross MA. Intravenous Immunoglobulin Therapy for Neuromuscular Disorders. Semin Neurol 2007; 27: 340-6.

  57. Plasma Exchange/Sandoglobulin Guillain-Barré Syndrome Trial Group. Randomised trial of plasma exchange, intravenous immunoglobulin, and plasma exchange followed by intravenous immunoglobulin in Guillain-Barré syndrome. Lancet 1997; 349: 225- 30.

  58. Dyck PJ, O’Brien PC, Oviatt KF, et al. Prednisone improves chronic inflammatory demyelinating polyradiculoneuropathy more than no treatment. Ann Neurol 1982; 11: 136-41.

  59. Hahn AF. Treatment of chronic inflammatory demyelinating polyneuropathy with intravenous immunoglobulin. Neurology 1998; 51: S16-S21.

  60. Hughes R, Bensa S, Willison H, et al. Randomized controlled trial of intravenous immunoglobulin versus oral prednisolone in chronic inflammatory demyelinating polyradiculoneuropathy. Ann Neurol 2001; 50: 195-201.

  61. Mendell JR, Barohn RJ, Freimer ML, et al. Randomized controlled trial of IVIg in untreated chronic inflammatory demyelinating polyradiculoneuropathy. Neurology 2001; 56: 445-9.

  62. Hahn AF, Bolton CF, Zochodne D, Feasby TE. Intravenous immunoglobulin treatment in chronic inflammatory demyelinating polyneuropathy. A double-blind, placebo controlled, cross-over study. Brain 1996; 119: 1067-77.

  63. Choudhary PP, Hughes RAC. Long-term treatment of chronic inflammatory demyelinating polyradiculoneuropathy with plasma exchange or intravenous immunoglobulin. Q J Med 1995; 88: 493– 502.

  64. van Doorn PA, Brand A, Strengers PFW, Meulstee J, Vermeulen M. High-dose intravenous immunoglobulin treatment in chronic inflammatory demyelinating polyneuropathy: a double-blind, placebocontrolled, crossover study. Neurology 1990; 40: 209-12.

  65. van Schaik IN, Winer JB, de Haan R, Vermeulen M. Intravenous immunoglobulin for chronic inflammatory demyelinating polyradiculoneuropathy: a systematic review. Lancet Neurol 2002; 1: 491-8.

  66. Nobile-Orazio E, Cappellari A, Priori A. Multifocal motor neuropathy: current concepts and controversies. Muscle Nerve 2005; 31: 663-80.

  67. Federico P, Zochodne DW, Hahn AF, Brown WF, Feasby TE. Multifocal motor neuropathy improved by IVIg: randomized, double-blind, placebo-controlled study. Neurology 2000; 55: 1256-62.

  68. Leger JM, Chassande B, Musset L, Meininger V, Bouche P, Baumann N. Intravenous immunoglobulin therapy in multifocal motor neuropathy: a double-blind, placebo-controlled study. Brain 2001; 124: 145-53.

  69. Van den Berg-Vos RM, Franssen H, Wokke JH, Van den Berg LH. Multifocal motor neuropathy: longterm clinical and electrophysiological assessment of intravenous immunoglobulin maintenance treatment. Brain 2002; 125: 1875-86.

  70. Dalakas MC. Intravenous Immunoglobulin in Autoimmune Neuromuscular Diseases. JAMA 2004; 291: 2367-75.

  71. Dalakas MC, Quarles RH, Farrer RG, et al. A controlled study of intravenous immunoglobulin in demyelinating neuropathy with IgM gammopathy. Ann Neurol 1996; 40: 792-5.

  72. Comi G, Roveri L, Swan A, et al. A randomised controlled trial of intravenous immunoglobulin in IgM paraprotein associated demyelinating neuropathy. J Neurol 2002; 249: 1370-7.

  73. Gajdos P, Tranchant C, Clair B, et al. Treatment of myasthenia gravis exacerbation with intravenous immunoglobulin 1g/kg versus 2g/kg: a randomized double blind clinical trial. Arch Neurol 2005; 62: 1689-93.

  74. Illa I. IVIg in myasthenia gravis, Lambert Eaton myasthenic syndrome and inflammatory myopathies: current status. J Neurol 2005; 252: 114-18.

  75. Fuchs S, Feferman T, Zhu KY, et al. Suppression of Experimental Autoimmune Myasthenia Gravis by Intravenous Immunoglobulin and Isolation of a Disease-Specific IgG Fraction. Ann NY Acad Sci 2007; 1110: 550-8.

  76. Bain PG, Motomura M, Newsom-Davis J, et al. Effects of intravenous immunoglobulin on muscle weakness and calcium-channel autoantibodies in the Lambert-Eaton myasthenic syndrome. Neurology 1996; 47: 678-83.

  77. Dalakas MC, Illa I, Dambrosia JM, et al. A controlled trial of high-dose intravenous immune globulin infusions as treatment for dermatomyositis. N Engl J Med 1993; 329: 1993-2000.

  78. Basta M, Dalakas MC. High-dose intravenous immunoglobulin exerts its beneficial effect in patients with dermatomyositis by blocking endomysial deposition of activated complement fragments. J Clin Invest 1994; 94: 1729-35.

  79. Cherin P, Pelletier S, Teixeira A, et al. Results and long-term followup of intravenous immunoglobulin infusions in chronic, refractory polymyositis: an open study with thirty five adult patients. Arthritis Rheum 2002; 46: 467-74.

  80. Dalakas MC, Sonies B, Dambrosia J, Sekul E, Cupler E, Sivakumar K. Treatment of inclusion body myositis with IVIg: a double-blind, placebo-controlled study. Neurology 1997; 48: 712-16.

  81. Dalakas MC, Koffman B, Fujii M, Spector S, Sivakumar K, Cupler E. A controlled study of intravenous immunoglobulin combined with prednisone in the treatment of IBM. Neurology 2001; 56: 323-7.

  82. Cherin P, Pelletier S, Teixeira A, et al. Intravenous immunoglobulin for dysphagia of inclusion body myositis. Neurology 2002; 58: 326.

  83. Sekul EA, Cupler EJ, Dalakas MC. Aseptic meningitis associated with high-dose intravenous immunoglobulin therapy: frequency and risk factors. Ann Intern Med 1994; 121: 259-62.

  84. Hamrock DJ. Adverse events associated with intravenous immunoglobulin therapy. International Immunopharmacology 2006; 6: 535-42.

  85. Dalakas MC. The use of intravenous immunoglobulin in the treatment of autoimmune neuromuscular diseases: evidence-based indications and safety profile. Pharmacol Ther 2004; 102: 177-93.

  86. Caress JB, Cartwright MS, Donofrio PD, Peacock Jr JE. The clinical features of 16 cases of stroke associated with administration of IGIV. Neurology 2003; 60: 1822- 4.




2020     |     www.medigraphic.com